Status:
COMPLETED
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Lead Sponsor:
Sumitomo Pharma America, Inc.
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medication...
Eligibility Criteria
Inclusion
- Subject has completed 6 weeks of treatment and all required assessments on the final study visit (Visit 8) of Study D1050289 (NCT01143077).
Exclusion
- Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or damage to property.
- Subject has a body mass index (BMI) greater than 40 or less than 18 kg/m2 (see Appendix 3 for BMI determination).
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT01143090
Start Date
August 1 2010
Last Update
June 12 2015
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
K and S Professional Research Services
Little Rock, Arkansas, United States, 72201
2
Synergy Clinical Research of Escondido
Escondido, California, United States, 92025
3
Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States, 92845
4
Pacific Research Partners, LLC
Oakland, California, United States, 94612